Daré Bioscience, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DARE research report →
Companywww.darebioscience.com
Daré Bioscience, Inc. , a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health.
- CEO
- Sabrina Martucci Johnson
- IPO
- 2014
- Employees
- 21
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $22.19M
- P/E
- -2.81
- P/S
- 19.17
- P/B
- 46.07
- EV/EBITDA
- -1.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 5.57%
- Op Margin
- -1034.38%
- Net Margin
- -1038.77%
- ROE
- 763.44%
- ROIC
- -151.18%
Growth & Income
- Revenue
- $1.03M · 10429.36%
- Net Income
- $-13,399,274 · -230.55%
- EPS
- $-1.20 · -150.00%
- Op Income
- $-13,552,334
- FCF YoY
- -213141.27%
Performance & Tape
- 52W High
- $9.19
- 52W Low
- $1.27
- 50D MA
- $2.06
- 200D MA
- $1.99
- Beta
- 1.09
- Avg Volume
- 598.92K
Get TickerSpark's AI analysis on DARE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 18, 26 | JOHNSON SABRINA MARTUCCI | other | 21,600 |
| Feb 18, 26 | JOHNSON SABRINA MARTUCCI | other | 10,800 |
| Jan 30, 26 | JOHNSON SABRINA MARTUCCI | other | 172,000 |
| Jan 30, 26 | Haring-Layton MarDee | other | 49,000 |
| Sep 4, 25 | Haring-Layton MarDee | other | 57,000 |
| Jul 9, 25 | RASTETTER WILLIAM H | other | 4,500 |
| Jul 9, 25 | Steele Robin Joan | other | 4,500 |
| Jul 9, 25 | Matz Gregory W | other | 4,500 |
| Jul 9, 25 | Grossman Jessica D. | other | 4,500 |
| Jul 9, 25 | Kelley Susan L. | other | 4,500 |
Our DARE Coverage
We haven't published any research on DARE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DARE Report →